Data Support Twice Yearly Exenatide 'Minipump' for DiabetesData Support Twice Yearly Exenatide 'Minipump' for Diabetes

An investigational subdermal device that delivers the GLP-1 agonist exenatide for 6 to 12 months in patients with type 2 diabetes reduced HbA1c and lowered weight in phase 3 studies. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news